Sign in
APGN Stock Price, Chart, Stats & News
Apexigen, Inc.
Save
9.57M
Market cap
–
Current P/E
–
Forward P/E
APGN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 1.92% |
ROA | -137.62% |
ROE | 48.27% |
D/E | 0.02x |
Interest coverage ratio | 52.98x |
APGN valuation
P/E | – |
P/S | – |
P/B | 1.19x |
P/CF | -0.25x |
P/FCF | -0.31x |
P/OCF | -0.25x |
PEG | -0.00x |
EV multiple | -0.75x |
About
Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials.
Similar securities
Based on sector and market capitalization
Report issue